Developer docs
API playgroundTry for free, no card

Search company profiles

SCI Ventures

Full company profile

uuid0009q7i

Namestring
SCI Ventures
Legal namestring
SCI Ventures
Websiteurl
sciventures.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

SCI Ventures is a London-headquartered, evergreen venture philanthropy fund founded in 2023 as the first specialist venture vehicle dedicated to curing paralysis. It invests globally at Seed and Series A stages into biotech and neurotechnology companies developing therapies for spinal cord injury (SCI), spanning therapeutic peptides, small molecule drugs, gene therapies, brain-computer interfaces, electrical stimulation, and assistive technologies. The portfolio comprises eight companies including NervGen Pharma, Axonis Therapeutics, EG 427, and Precision Neuroscience.

The fund's structure is distinctive: it is co-created and underwritten by five leading global SCI foundations (Christopher & Dana Reeve Foundation, Shepherd Center, Spinal Research, Wings for Life, Promobilia Foundation), with the Reeve Foundation covering all initial operating costs so that 100% of returns and donated capital can be reinvested into the portfolio. Governance combines an Investment Committee staffed by senior ex-VC/CIO operators (BC Partners, 3i, Jefferies, Lazard, PwC) with a Scientific Advisory Council of leading academic neuroscientists and SCI clinicians. SCI Ventures' competitive position rests on exclusive access to foundation networks, patient communities, and standardized pre-clinical pipelines that no generalist VC replicates.

Commercially, SCI Ventures targets an addressable population of 15 million people worldwide living with SCI, where average lifetime care costs reach $4 million and typical onset is under age 39. The fund has catalyzed over $500 million in follow-on capital from top-tier VCs into its portfolio companies and has expanded into AI-assisted drug discovery via a partnership with Healx, while adding Craig Hospital as a sixth alliance partner with board representation.

Short descriptiontext

SCI Ventures is a London-based evergreen venture philanthropy fund founded in 2023, the first specialist VC dedicated to curing paralysis. It invests globally at Seed and Series A into biotech and neurotechnology companies developing spinal cord injury therapies, backed by five leading global SCI foundations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital fund, spinal cord injury, neurotechnology investments, biotech investments, paralysis therapies
Industry3 codes
PRIMARYFSANAGAC
Venture Capital Fund-of-Funds
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code1 code
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Healthcare Impact Investing
No data
Revenue model1 record
1Investment Returns
TypeLicensing Royalties
Description

SCI Ventures operates as an evergreen fund where all investment returns are recycled and reinvested within the fund to take more targeted shots at curing paralysis. The fund makes investments with the intent of generating a financial return while catalyzing therapies for spinal cord injury.

sciventures.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SCI Ventures is an evergreen venture philanthropy fund that invests in early-stage biotech and neurotechnology companies developing cure-oriented therapies for spinal cord injury and paralysis, typically at Seed and Series A stages. The fund provides capital, clinical expertise, and patient community connections, with all returns recycled and reinvested within the fund to catalyze cures for paralysis.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

SCI Ventures is an evergreen venture philanthropy fund dedicated to catalyzing innovative cures for paralysis. The fund invests in early-stage companies developing cure-oriented therapies for spinal cord injury and related neurological conditions, typically at Seed and Series A stages. Backed by leading foundations including the Christopher & Dana Reeve Foundation, Shepherd Center, Spinal Research, Wings for Life, and Promobilia Foundation, the fund provides capital as well as clinical expertise and patient community connections to support portfolio companies. All returns are recycled and reinvested within the fund to take more targeted shots at the goal of curing paralysis. The fund's portfolio spans therapeutic peptides, small molecule drugs, gene therapies, brain-computer interfaces, electrical stimulation, and assistive technologies.

Product and service1 record
1SCI Ventures Evergreen Fund
CategoryVenture Capital Fund
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Craig Hospital
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

Craig Hospital, a nationally recognized neurorehabilitation hospital specializing in spinal cord and brain injury care, has joined SCI Ventures as an Alliance Partner. The partnership includes an investment in the fund and representation on the board of directors. Craig Hospital contributes clinical expertise and direct patient community connections to advance the fund's mission of bringing new therapies to persons living with paralysis.

pulse2.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-17
Description

SCI Ventures partnered with Healx to create a neuro-regeneration program with a focus on chronic spinal cord injury. Healx contributes its AI platform for drug discovery to identify novel therapeutic targets and match them with repurposable drugs for accelerated development of treatments for the 20 million people globally affected by paralysis.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment8 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SCI Ventures

Venture Capital / Healthcare Impact Investingsciventures.com

SCI Ventures is a London-based evergreen venture philanthropy fund founded in 2023, the first specialist VC dedicated to curing paralysis. It invests globally at Seed and Series A into biotech and neurotechnology companies developing spinal cord injury therapies, backed by five leading global SCI foundations.

What SCI Ventures does

SCI Ventures is a London-headquartered, evergreen venture philanthropy fund founded in 2023 as the first specialist venture vehicle dedicated to curing paralysis. It invests globally at Seed and Series A stages into biotech and neurotechnology companies developing therapies for spinal cord injury (SCI), spanning therapeutic peptides, small molecule drugs, gene therapies, brain-computer interfaces, electrical stimulation, and assistive technologies. The portfolio comprises eight companies including NervGen Pharma, Axonis Therapeutics, EG 427, and Precision Neuroscience.

The fund's structure is distinctive: it is co-created and underwritten by five leading global SCI foundations (Christopher & Dana Reeve Foundation, Shepherd Center, Spinal Research, Wings for Life, Promobilia Foundation), with the Reeve Foundation covering all initial operating costs so that 100% of returns and donated capital can be reinvested into the portfolio. Governance combines an Investment Committee staffed by senior ex-VC/CIO operators (BC Partners, 3i, Jefferies, Lazard, PwC) with a Scientific Advisory Council of leading academic neuroscientists and SCI clinicians. SCI Ventures' competitive position rests on exclusive access to foundation networks, patient communities, and standardized pre-clinical pipelines that no generalist VC replicates.

Commercially, SCI Ventures targets an addressable population of 15 million people worldwide living with SCI, where average lifetime care costs reach $4 million and typical onset is under age 39. The fund has catalyzed over $500 million in follow-on capital from top-tier VCs into its portfolio companies and has expanded into AI-assisted drug discovery via a partnership with Healx, while adding Craig Hospital as a sixth alliance partner with board representation.

SCI Ventures firmographics

Firmographics
Name
SCI Ventures
Legal name
SCI Ventures
Website
https://sciventures.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
SCI Ventures is a London-based evergreen venture philanthropy fund founded in 2023, the first specialist VC dedicated to curing paralysis. It invests globally at Seed and Series A into biotech and neurotechnology companies developing spinal cord injury therapies, backed by five leading global SCI foundations.
Ownership category
akta.pro rank

SCI Ventures industry classification

Industry
Product category
Venture Capital / Healthcare Impact Investing
NAICS
Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAGAC
Venture Capital Fund-of-Funds
Financial & Insurance/Private Equity & Venture Capital/Fund-of-Funds / Multi-Manager Platforms
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Venture capital fund
  • Spinal cord injury
  • Neurotechnology investments
  • Biotech investments
  • Paralysis therapies

Where SCI Ventures is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

SCI Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Others

Revenue model

  1. Investment Returns: SCI Ventures operates as an evergreen fund where all investment returns are recycled and reinvested within the fund to take more targeted shots at curing paralysis. The fund makes investments with the intent of generating a financial return while catalyzing therapies for spinal cord injury.

Distribution channels1 record

Marketing channels3 records

SCI Ventures product offering

Product offering

Core offering

SCI Ventures is an evergreen venture philanthropy fund that invests in early-stage biotech and neurotechnology companies developing cure-oriented therapies for spinal cord injury and paralysis, typically at Seed and Series A stages. The fund provides capital, clinical expertise, and patient community connections, with all returns recycled and reinvested within the fund to catalyze cures for paralysis.

Product overview

SCI Ventures is an evergreen venture philanthropy fund dedicated to catalyzing innovative cures for paralysis. The fund invests in early-stage companies developing cure-oriented therapies for spinal cord injury and related neurological conditions, typically at Seed and Series A stages. Backed by leading foundations including the Christopher & Dana Reeve Foundation, Shepherd Center, Spinal Research, Wings for Life, and Promobilia Foundation, the fund provides capital as well as clinical expertise and patient community connections to support portfolio companies. All returns are recycled and reinvested within the fund to take more targeted shots at the goal of curing paralysis. The fund's portfolio spans therapeutic peptides, small molecule drugs, gene therapies, brain-computer interfaces, electrical stimulation, and assistive technologies.

Differentiator

Problem solved

Functional benefit

Products and services

  • SCI Ventures Evergreen Fund

Companies that use SCI Ventures

Customer profile

Segments1 record

Ideal customer profiles1 record

SCI Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

SCI Ventures partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Craig HospitalflagshipStrategic or Co-development Partner · 22 June 2026Craig Hospital, a nationally recognized neurorehabilitation hospital specializing in spinal cord and brain injury care, has joined SCI Ventures as an Alliance Partner. The partnership includes an investment in the fund and representation on the board of directors. Craig Hospital contributes clinical expertise and direct patient community connections to advance the fund's mission of bringing new therapies to persons living with paralysis.
  • HealxcoreStrategic or Co-development Partner · 17 July 2025SCI Ventures partnered with Healx to create a neuro-regeneration program with a focus on chronic spinal cord injury. Healx contributes its AI platform for drug discovery to identify novel therapeutic targets and match them with repurposable drugs for accelerated development of treatments for the 20 million people globally affected by paralysis.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

SCI Ventures competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

SCI Ventures compliance and trust

Trust signal

Compliance1 record

SCI Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SCI Ventures leadership team

Management profile

Number of profiles

Profiles11 records

SCI Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SCI Ventures M&A and investment

M&A and investment

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SCI Ventures

What does SCI Ventures do?

SCI Ventures is an evergreen venture philanthropy fund that invests in early-stage biotech and neurotechnology companies developing cure-oriented therapies for spinal cord injury and paralysis, typically at Seed and Series A stages. The fund provides capital, clinical expertise, and patient community connections, with all returns recycled and reinvested within the fund to catalyze cures for paralysis.

Is SCI Ventures a public or private company?

SCI Ventures is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was SCI Ventures founded?

SCI Ventures was founded in 2023. It employs 1 to 10 people.

Where is SCI Ventures based?

SCI Ventures is headquartered in London, United Kingdom, in the Europe region.

How does SCI Ventures make money?

One revenue line is on record: investment Returns.

Does SCI Ventures have an API?

No public API is recorded for SCI Ventures.

What industry is SCI Ventures in?

SCI Ventures's product category is Venture Capital / Healthcare Impact Investing. Its primary akta.pro industry code is FSANAGAC, Venture Capital Fund-of-Funds, with a secondary code of BPAGAKAI, Research & Science Grantmaking Foundations. Its NAICS code is 5259 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceViaNautis Bio welcomes SCI Ventures as new investor, expanding CNS portfolio into spinal cord injuryViaNautis Bio announced SCI Ventures as a new investor, expanding its CNS portfolio into spinal cord injury. The investment supports applying polyNaut® for targeted delivery of regenerative therapies, addressing a key barrier in the field. Spinal cord injury affects over 20 million people globally.VianautisViaNautis Bio welcomes SCI Ventures as new investor, expanding CNS portfolio into spinal cord injury < ViaNautisViaNautis Bio announced SCI Ventures as a new investor, expanding its CNS portfolio into spinal cord injury. The investment supports applying polyNaut® for targeted delivery of regenerative therapies, addressing a key barrier in the field. Spinal cord injury affects over 20 million people globally.StartupmagBiotech firm ViaNautis raises £20m backed by SCI Ventures and 4BIO CapitalViaNautis closed a £20m growth round with SCI Ventures and 4BIO Capital to advance its polyNaut non-viral delivery platform into regenerative therapies for chronic spinal cord injury. The funding will expand its CNS programme, targeting a high-unmet-need indication where delivery has blocked progress. The company will use the capital to extend preclinical work and test targeting strategies.LinkedInViaNautis Expands CNS Portfolio with SCI Venture InvestmentViaNautis announced an investment from SCI Ventures to expand its CNS portfolio into chronic spinal cord injury, affecting over 20 million people. The investment validates polyNaut as a platform for precise, non-viral delivery of genetic medicines, targeting spinal cord lesions.FinSMEsViaNautis Bio Receives Investment From SCI VenturesViaNautis Bio, a Cambridge-based company developing targeted polymer nanovesicles for genetic medicine delivery, received an undisclosed investment from SCI Ventures. The funds will support expanding its central nervous system portfolio into chronic spinal cord injury. The company's polyNaut platform is designed for non-viral, targeted delivery of DNA and mRNA.Pulse 2.0Craig Hospital Joins SCI Ventures As Alliance PartnerCraig Hospital announced it has joined SCI Ventures as an Alliance Partner, investing in the specialist venture fund and joining its board of directors. Through the partnership, Craig Hospital will contribute clinical expertise and connections to the patient community to support the development of therapies for paralysis and spinal cord injuries. SCI Ventures has built a portfolio of eight biotech and neurotechnology companies and has attracted over $500 million in follow-on investments from venture capital firms.Business Wire BlogCraig Hospital Joins SCI Ventures as Alliance Partner to Accelerate Innovation in Spinal Cord InjuryCraig Hospital, a nationally recognized neurorehabilitation hospital specializing in spinal cord and brain injury care, has joined SCI Ventures as an Alliance Partner to accelerate innovation in spinal cord injury treatment. Through the partnership, Craig Hospital will invest in the fund, join its board of directors, and contribute clinical expertise and patient community connections. SCI Ventures is the first specialist venture fund dedicated to paralysis, co-founded in 2023 by leading foundations including the Christopher & Dana Reeve Foundation and Shepherd Center, and has attracted over $500 million in follow-on investments from top-tier VCs.FinancialContent Business PageCraig Hospital Joins SCI Ventures as Alliance Partner to Accelerate Innovation in Spinal Cord InjuryCraig Hospital, a nationally recognized neurorehabilitation hospital specializing in spinal cord and brain injury care, announced it is joining SCI Ventures as an Alliance Partner and will invest in the fund while joining its board of directors. Through this partnership, Craig Hospital will contribute clinical expertise and direct patient community connections to advance the fund's mission of bringing new therapies to persons living with paralysis. SCI Ventures, the first specialist venture fund dedicated to paralysis co-founded by major foundations including the Christopher & Dana Reeve Foundation, has built a portfolio of eight biotech and neurotechnology companies and has attracted more than $500 million in follow-on investments.ChristopherreeveThe Science Is Ready. SCI Ventures Is Making Sure the World Is, Too.SCI Ventures, a spinal cord injury fund co-founded by the Reeve Foundation, has raised over $33 million since June 2024 and built a portfolio of eight early-stage companies. It is advancing therapies like EG 427's gene therapy and Axonis's oral drug, with NervGen's NVG-291 targeting Phase 3 trials and a Nasdaq listing.NervgenNervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 DevelopmentNervGen Pharma completed a US$10 million non-brokered private placement, issuing 4,785,674 units at US$2.10 per unit, with each unit comprising one common share and one-half of one warrant exercisable at US$2.65 over 36 months. The financing attracted participation from institutional and accredited investors including SCI Ventures, the Paul and Phyllis Fireman Charitable Foundation, and insider PFP Biosciences Holdings LLC, which acquired additional shares bringing its stake to 18.8% of outstanding common shares. Proceeds will fund the advancement of NVG-291 clinical development and support an anticipated Nasdaq listing.